Filter by financial year:
| Date | Particulars | |
|---|---|---|
| 24 December, 2025 | Completion of US-FDA Inspection at the Formulations Facility of Strides Pharma Inc., USA, a step-down wholly owned subsidiary of the Company |
|
| 22 December, 2025 | Intimation of closure of trading window – Q3FY26 |
|
| 03 December, 2025 | Movement in Senior Management Personnel |
|
| 17 October, 2025 | Strides and Incepta Partner to Expand Women’s Health Access with WHO-Prequalified Contraceptive |
|
| 25 September, 2025 | Intimation of closure of trading window - Q2FY26 |
|
| 24 September, 2025 | Sustainability Report FY25 |
|
| 08 September, 2025 | Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market |
|
| 25 August, 2025 | Deregistration of a non-operating step-down subsidiary of the Company in South Africa |
|
| 29 July, 2025 | Allotment of Shares |
|
| 29 July, 2025 | Amendment to Strides’ Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information |
|
